高级检索
当前位置: 首页 > 详情页

Distinct and overlapping roles of Hippo effectors YAP and TAZ during human and mouse hepatocarcinogenesis.

文献详情

资源类型:
Pubmed体系:
机构: [1]Liver Transplantation Division, Department of Liver Surgery, Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China [2]Department of Bioengineering and Therapeutic Sciences and Liver Center, University ofCalifornia, San Francisco,California [3]School of Life Sciences, BeijingUniversity ofChinese Medicine, Beijing, China [4]Department of Oncology and Hematology, The Second Hospital, Jilin University, Changchun, China [5]School of Pharmacy, Hubei University of Chinese Medicine Wuhan, Hubei, China [6]Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, East Lansing, Michigan [7]Department of Pharmacology and Toxicology, College of Human Medicine, Michigan State University, East Lansing, Michigan [8]Institute of Pathology, University of Greifswald, Greifswald, Germany [9]Institute of Pathology, University Clinic of Regensburg, Regensburg, Germany
出处:

关键词: YAP TAZ Hepatocellular Carcinoma Cell Cycle

摘要:
Yes-associated protein (YAP) and its paralog transcriptional co-activator with PDZ-binding motif (TAZ) are two co-activators downstream of Hippo tumor suppressor cascade. Both have been implicated in the development of hepatocellular carcinoma (HCC). However, whether YAP and TAZ have distinct or overlapping functions during hepatocarcinogenesis remains unknown. Expression patterns of YAP and TAZ were analyzed in human HCC samples. The requirement of Yap and/or Taz in Akt/NRas driven liver tumorigenesis was analyzed using conditional Yap, Taz, and Yap;Taz knockout mice. Transcriptional programs regulated by YAP and/or TAZ were identified via RNASeq. We found that in human HCC samples, an almost ubiquitous activation of YAP or TAZ occurs, underlying their role in this tumor type. Intriguingly, 70% of HCC samples displayed only nuclear YAP or TAZ immunoreactivity. In the Akt/NRas liver tumor model, where nuclear Yap and Taz can be readily detected, deletion of Yap or Taz alone only mildly delayed liver tumor development, whereas their concomitant ablation strongly inhibited tumor cell proliferation and significantly suppressed Akt/NRas driven hepatocarcinogenesis. In HCC cell lines, silencing of either YAP or TAZ led to decreased expression of both overlapping and distinct sets of genes, with the most prominent gene signatures related to cell cycle progression and DNA replication. YAP and TAZ have overlapping and distinct roles in hepatocarcinogenesis. HCCs may display unique activation of YAP or TAZ, thus relying on either YAP or TAZ for their growth. Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 1 区 医学
小类 | 2 区 胃肠肝病学
最新[2023]版:
大类 | 1 区 医学
小类 | 2 区 胃肠肝病学
第一作者:
第一作者机构: [1]Liver Transplantation Division, Department of Liver Surgery, Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China [2]Department of Bioengineering and Therapeutic Sciences and Liver Center, University ofCalifornia, San Francisco,California
共同第一作者:
通讯作者:
通讯机构: [1]Liver Transplantation Division, Department of Liver Surgery, Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China [2]Department of Bioengineering and Therapeutic Sciences and Liver Center, University ofCalifornia, San Francisco,California [9]Institute of Pathology, University Clinic of Regensburg, Regensburg, Germany [*1]Institute of Pathology, University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany. [*2]Department of Liver Surgery, Liver Transplantation Division, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan 610041, China [*3]Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California 94143.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43389 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号